Patents by Inventor Alain Tedgui

Alain Tedgui has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8586822
    Abstract: The present invention relates to methods for producing a non human animal model for aortic aneurysm which could provide insight into the diagnosis and treatment of disease. Furthermore, the present invention relates to methods and compositions for the treatment or the prevention of aneurysm in a subject in need thereof.
    Type: Grant
    Filed: September 30, 2008
    Date of Patent: November 19, 2013
    Assignee: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Pierre Louis Tharaux, Hafid Ait-Oufella, Alain Tedgui, Ziad Mallat
  • Publication number: 20130224215
    Abstract: The present invention relates to the prevention or treatment of atherosclerosis, in particular to a B cell depleting agent for the prevention or treatment of atherosclerosis.
    Type: Application
    Filed: March 8, 2013
    Publication date: August 29, 2013
    Inventors: Ziad Mallat, Hafid Ait-Oufella, Alain Tedgui, Thomas Tedder
  • Patent number: 8383355
    Abstract: The present invention related to a method of identifying a subject having or at risk of having or developing a cardiovascular disease and/or a cardiovascular event, comprising: —measuring, in a sample obtained from said subject, at least two cardiovascular risk factors: a) sPLA2 type HA mass and b) oxidized phospholipids on apolipoprotein B-IOO particles (OxPL/apoB), —combining said measurements, the combined value of sPLA2 type HA mass and OxPL/apoB being indicative of having or a risk of having or developing a cardiovascular disease and/or cardiovascular event.
    Type: Grant
    Filed: December 8, 2009
    Date of Patent: February 26, 2013
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), The Regents of the University of California
    Inventors: Ziad Mallat, Alain Tedgui, Sotirios Tsimikas, Joseph Witztum
  • Patent number: 8361732
    Abstract: The use of a combination of sPLA2 activity and OxPL/apoB cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event or for the monitoring of a cardiovascular disease.
    Type: Grant
    Filed: March 9, 2012
    Date of Patent: January 29, 2013
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), The Regents of the University of California, Universite Paris Diderot—Paris 7
    Inventors: Ziad Mallat, Alain Tedgui, Sotirios Tsimikas, Joseph Witztum
  • Publication number: 20130017557
    Abstract: The present invention related to a method of identifying a subject having or at risk of having or developing a cardiovascular disease and/or a cardiovascular event, comprising: —measuring, in a sample obtained from said subject, at least two cardiovascular risk factors: a) sPLA2 type HA mass and b) oxidized phospholipids on apolipoprotein B-IOO particles (OxPL/apoB), —combining said measurements, the combined value of sPLA2 type HA mass and OxPL/apoB being indicative of having or a risk of having or developing a cardiovascular disease and/or cardiovascular event.
    Type: Application
    Filed: December 8, 2009
    Publication date: January 17, 2013
    Inventors: Ziad Mallat, Alain Tedgui, Sotirios Tsimikas, Joseph Witztum
  • Publication number: 20120321650
    Abstract: Epitopes derived from a protein present in an atherosclerotic plaque, such as apolipoprotein B-100, are presented. The epitopes can be used in a method of treating atherosclerosis by continuous subcutaneous or transcutaneous administration of a therapeutically effective amount of the epitope to a subject. Administering the epitope to the subject can induce a specific regulatory immune response, such as a Treg response. A composition or patch containing the epitope and adapted for the prophylactic or therapeutic treatment of a subject are also presented.
    Type: Application
    Filed: August 1, 2012
    Publication date: December 20, 2012
    Applicant: Institut National De La Sante Et De La Recherche Medicale (Inserm)
    Inventors: Alain TEDGUI, Ziad MALLAT
  • Patent number: 8324152
    Abstract: The present invention concern a composition or a patch adapted for the prophylactic or therapeutic treatment by continuous subcutaneous administration of a subject suffering from atherosclerosis, comprising an effective amount of at least one epitope derived from a protein present in the atherosclerotic plaque, whereby administration of said at least one epitope to said subject induces a specific regulatory immune response, preferably a Treg response.
    Type: Grant
    Filed: January 4, 2006
    Date of Patent: December 4, 2012
    Assignee: Institute National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Alain Tedgui, Ziad Mallat
  • Publication number: 20120207722
    Abstract: This invention relates to the use of cells of a medullary or extra-medullary white adipose tissue, in particular of an extra-medullary stromal vascular fraction (SVF) and/or mature dedifferentiated adipocytes of any origin for initiating the formation of a functional vascularisation.
    Type: Application
    Filed: February 8, 2012
    Publication date: August 16, 2012
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, UNIVERSITE PARIS VII (DENIS DIDEROT), UNIVERSITE PAUL SABATIER
    Inventors: Louis Casteilla, Jean-Sébastien Silvestre, Valérie Planat-Benard, Bernard Levy, Luc Penicaud, Alain Tedgui
  • Publication number: 20120171705
    Abstract: The use of a combination of sPLA2 activity and OxPL/apoB cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event or for the monitoring of a cardiovascular disease.
    Type: Application
    Filed: March 9, 2012
    Publication date: July 5, 2012
    Applicants: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS DIDEROT - PARIS 7, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Ziad Mallat, Alain Tedgui, Sotirios Tsimikas, Joseph Witztum
  • Patent number: 8187818
    Abstract: A method for determining an increased risk of mortality or of a cardiac and/or vascular event in a patient, includes:—determining the sPLA2 activity of the patient as a first risk marker—determining at least the value of a second risk marker chosen among CRP level, IgM IC of apo B 100 level or IgM MDA-LDL level—determining the ratio (odds ratio) between the value of the sPLA2 activity and the value of the second risk marker and comparing it to a predetermined odds ratio, the odds ratio compared to the predetermined odds ratio being indicative of an increased risk of mortality or of a cardiac and/or vascular event. A new micro method adaptation for automated fluorimetric measurement of serum secretory phospholipase A2 is also disclosed.
    Type: Grant
    Filed: July 31, 2007
    Date of Patent: May 29, 2012
    Assignees: Assistance Publique—Hopitaux de Paris, Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Alain Tedgui, Ziad Mallat, Joëlle Benessiano
  • Publication number: 20120116817
    Abstract: The present invention relates to a method for predicting cardiovascular mortality risk in a patient, comprising determining the level of endothelial microparticles in a blood sample obtained from said patient.
    Type: Application
    Filed: June 30, 2010
    Publication date: May 10, 2012
    Inventors: Chantal Boulanger, Alain Tedgui, Gérard London
  • Patent number: 8163504
    Abstract: A method of identifying a subject having or at risk of having or developing a cardiovascular disease and/or a cardiovascular event, includes: measuring, in a sample obtained from the subject, at least two cardiovascular risk factors: a) sPLA2 activity and b) oxidized phospholipids on apolipoprotein B-100 particles (OxPL/apoB), combining the measurements, the combined value of sPLA2 activity and OxPL/apoB being indicative of having or a risk of having or developing a cardiovascular disease and/or cardiovascular event.
    Type: Grant
    Filed: October 2, 2009
    Date of Patent: April 24, 2012
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), The Regents of the University of California, Universite Paris Diderot-Paris 7
    Inventors: Ziad Mallat, Alain Tedgui, Sotirios Tsimikas, Joseph Witztum
  • Publication number: 20120076754
    Abstract: The present invention relates to the prevention or treatment of atherosclerosis, using an IL-17 polypeptide and pharmaceutical compositions thereof.
    Type: Application
    Filed: May 20, 2010
    Publication date: March 29, 2012
    Inventors: Ziad Mallat, Alain Tedgui, Soraya Taleb
  • Publication number: 20110275791
    Abstract: The present invention relates to the prevention or treatment of atherosclerosis, in particular to a B cell depleting agent for the prevention or treatment of atherosclerosis.
    Type: Application
    Filed: January 5, 2010
    Publication date: November 10, 2011
    Inventors: Ziad Mallat, Hafid Ait-Oufella, Alain Tedgui, Thomas Tedder
  • Publication number: 20110229919
    Abstract: A method of identifying a subject having or at risk of having or developing a cardiovascular disease and/or a cardiovascular event, includes: measuring, in a sample obtained from the subject, at least two cardiovascular risk factors: a) sPLA2 activity and b) oxidized phospholipids on apolipoprotein B-100 particles (OxPL/apoB), combining the measurements, the combined value of sPLA2 activity and OxPL/apoB being indicative of having or a risk of having or developing a cardiovascular disease and/or cardiovascular event.
    Type: Application
    Filed: October 2, 2009
    Publication date: September 22, 2011
    Applicants: INSERM (INSTITUT NATIONAL DE LA SAINTE ET DE LA RECHERCHE MEDICALE), THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, UNIVERSITE PARIS DIDEROT-PARIS 7
    Inventors: Ziad Mallat, Alain TedguI, Sotirios Tsimikas, Joseph Witztum
  • Patent number: 7985409
    Abstract: The present invention relates to a method of treating or preventing atherosclerosis comprising administering to a mammal in need of such a treatment a) an antigen which has been used to activate in vitro a Tri cell population originating from said mammal, and b) the TO cell population activated by said antigen, said TO cell population being obtained from a CD4+ T lymphocyte population of said mammal.
    Type: Grant
    Filed: August 11, 2004
    Date of Patent: July 26, 2011
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), TxCell
    Inventors: Hervé Groux, Alain Tedgui, Ziad Mallat, Valérie Brun
  • Publication number: 20100291028
    Abstract: The invention relates to the use of an inhibitor of IL-18 in the preparation of a medicament for treatment and/or prevention of peripheral vascular diseases. The invention further relates to the use of an IL-18 inhibitor for prevention of limb amputation.
    Type: Application
    Filed: June 1, 2010
    Publication date: November 18, 2010
    Applicants: MERCK SERONO SA, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
    Inventors: Yolande Chvatchko, Alain Tedgui, Ziad Mallat
  • Publication number: 20100260726
    Abstract: The present invention relates to methods for producing a non human animal model for aortic aneurysm which could provide insight into the diagnosis and treatment of said disease. Furthermore, the present invention relates to methods and compositions for the treatment or the prevention of aneurysm in a subject in need thereof.
    Type: Application
    Filed: September 30, 2008
    Publication date: October 14, 2010
    Applicant: INSERM
    Inventors: Pierre Louis Tharaux, Hafid Ait-Oufella, Alain Tedgui, Ziad Mallat
  • Publication number: 20100256045
    Abstract: The present invention relates to the use of the measles virus nucleoprotein (NP), fragments or variants thereof for the treatment and/or the prevention of atherosclerosis.
    Type: Application
    Filed: October 25, 2007
    Publication date: October 7, 2010
    Inventors: Ziad Mallat, Alain Tedgui, Branka Horvat
  • Publication number: 20090325194
    Abstract: A method for determining an increased risk of mortality or of a cardiac and/or vascular event in a patient, includes:—determining the sPLA2 activity of the patient as a first risk marker—determining at least the value of a second risk marker chosen among CRP level, IgM IC of apo B 100 level or IgM MDA-LDL level—determining the ratio (odds ratio) between the value of the sPLA2 activity and the value of the second risk marker and comparing it to a predetermined odds ratio, the odds ratio compared to the predetermined odds ratio being indicative of an increased risk of mortality or of a cardiac and/or vascular event. A new micro method adaptation for automated fluorimetric measurement of serum secretory phospholipase A2 is also disclosed.
    Type: Application
    Filed: July 31, 2007
    Publication date: December 31, 2009
    Applicant: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
    Inventors: Alain Tedgui, Ziad Mallat, Joëlle Benessiano